|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
DAILY VOLUME INDEX
Trading: SELL @ $1.8
Signal Strength: MEDIUM
Mesoblast (ASX:MSB) current distribution has given weakness to the share price and the continuation of bearish trading conditions. Currently, the DVI is -14618.
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading exit. Indicator can be applied to the short/medium term timeframe, but the best results are obtained with larger cyclical swings in-line with the trend direction. This accumulation / distribution oscillator can provide guidance on the money flow direction from the companies recent trading.
The daily volume index (DVI) is the amount of individual securities traded in a day on average over a specified period of time. Trading activity relates to the liquidity of a security. When average daily trading volume is high the stock can be easily traded and has high liquidity if trading volume is not very high and the security will tend to be less expensive because people are not as willing to buy it. As a result average daily trading volume can have an effect on the price of the security.
Calculation: Daily Volume Index (DVI):
1) [Close]-[Average price] / [Average price] x [Volume];
PROFILE: Mesoblast (MSB.AX)
Stock Exchange: ASX
Ticker Codes: | MSB.AX | ASX:MSB |
Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions. The company's products under the Phase III clinical trials include MPC-150-IM for chronic and end-stage heart failure; MPC-06-ID for chronic low back pain; and MSC-100-IV for acute graft versus host disease in children. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, and diabetic kidney diseases and type 2 diabetes. The company has a collaboration agreement with JCR Pharmaceuticals Co., Ltd. It has operations in the United States, Australia, Singapore, and Switzerland. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.
|EMH European Metals Holdings||0.36||12.5||74,674||-10||BEARISH|
|MNS Milnes Holdings||0.12||9.1||1,220,042||-9,926||BEARISH|
|GGG Greenland Minerals||0.12||9.1||3,783,020||-13,156||BEARISH|
|SYR Syrah Resources||0.49||5.4||4,913,585||-25,302||BEARISH|
|OGC Oceanagold Corporation||3.29||5.4||244,731||-240||BEARISH|
|CLQ Clean Teq Holdings||0.25||4.2||1,049,067||-11,592||BEARISH|
|AHY Asaleo Care||1.02||4.1||640,185||-1,189||BEARISH|